Effect of oral curcuden on multiple sclerosis patients

INTERVENTION: Intervention 1: Intervention group 1: 34 RRMS patients who received at least 6 months of first line treatment of MS (beta‐interferon) but have clinically experienced at least one relapse during medication or an active lesion in their brain or spinal cord. Intervention 2: Control group: 34 RRMS patients who receive at least 6 months of first line treatment of MS (beta‐interferon) but have clinically experienc at least one relapse during medication or an active lesion in their brain or spinal cord. CONDITION: Multiple sclerosis. ; Demyelinating diseases of the central nervous system(Multiple sclerosis) PRIMARY OUTCOME: Active lesions in the brain and spinal cord (plaque). Timepoint: Before the intervention (month 0) and the sixth month after the intervention. Method of measurement: MRI. Blood inflammatory factors. Timepoint: Before the intervention (month 0) and the sixth month after the intervention. Method of measurement: Blood Test. SECONDARY OUTCOME: Clinical relapse within 6 months. Timepoint: Every 6 months. Method of measurement: MRI. Effect of medication on changes in inflammatory and anti‐inflammatory mediators. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Blood test. Effect of medication on improving patient lifestyle. Timepoint: Before intervention and 6 months after intervention. Method of measurement: EDSS Criteria, Fatigue, Focus, Balance . Effect of medication on other MRI parameters such as T2 lesions, new T2 lesions and brain atrophy. Timepoint: Every 6 months. Method of measurement: MRI. INCLUSION CRITERIA: RRMS patients who will receive first‐line treatment drugs for one year Have at least one relapse or active lesion At least one month has passed since the last attack of the disease At least one month ha passed from the patient's corticosteroids Average age of 18 to 60 years 0

Epistemonikos ID: 953099000f3a621d7365417b3bcca6546b70c1d3
First added on: Mar 31, 2022